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UL18 is a human cytomegalovirus class I MHC (MHCI) homolog that
binds the host inhibitory receptor LIR-1 and the only known viral
MHC homolog that presents peptides. The 2.2-Å structure of a
LIR-1/UL18/peptide complex reveals increased contacts and opti-
mal surface complementarity in the LIR-1/UL18 interface compared
with LIR/MHCI interfaces, resulting in a>1,000-fold higher affinity.
Despite sharing only25% sequence identity, UL18’s structure and
peptide binding are surprisingly similar to host MHCI. The crystal
structure suggests that most of the UL18 surface, except where
LIR-1 and the host-derived light chain bind, is covered by carbo-
hydrates attached to 13 potential N-glycosylation sites, thereby
preventing access to bound peptide and association with most
MHCI-binding proteins. The LIR-1/UL18 structure demonstrates
how a viral protein evolves from its host ancestor to im-
pede unwanted interactions while preserving and improving its
receptor-binding site.
cytomegalovirus  immune evasion  LIR-1  x-ray crystallography
Human cytomegalovirus (HCMV) is prevalent among all hu-man populations, infecting 70–90% of adults (1). HCMV
infection is usually asymptomatic in immunocompetent individuals,
but the virus causes a latent infection that can be reactivated during
immune suppression. To maintain persistence in the presence of a
primed immune system, HCMV has developed mechanisms to
subvert the host immune response (2). One strategy is to down-
regulate cell surface expression of host class I MHC molecules,
thereby allowing HCMV-infected cells to avoid recognition by
virus-specific cytotoxic T cells. However, cells that lack surface class
IMHCmolecules are susceptible to lysis by natural killer (NK) cells
(3). NK cells express both activating receptors and inhibitory
receptors, many of which recognize class I MHC molecules (4).
Stimulation of the activating receptors leads to lysis of target cells
when expression of class I MHC proteins is down-regulated (5);
however, clinical isolates of HCMV can evade NK lysis (6) by
down-regulation (7) or inhibition (8) of the activating ligands for
NK cells; up-regulation of HLA-E (9), which binds the NK cell
inhibitory receptor NKG2A/CD94; and potentially through the
expression of two virally encoded class I MHC homologs, UL142
(10) and UL18 (11).
UL18 is a heavily glycosylated transmembrane protein that
shares 25% sequence identity with class I MHC molecules (11).
It associates with the class I MHC light chain, 2-microglobulin
(2m) (12), and with endogenous peptides derived from cytoplas-
mic proteins that resemble those bound to host class I proteins (13).
Peptide binding renders UL18 unique among viralMHC homologs
and unusual among host MHC homologs. The role of UL18 in NK
cell recognition is controversial; it has been reported to inhibit
NK-cell-mediated lysis in some experimental conditions but not
others (14).
The only host receptor identified for UL18 is LIR-1 (15) (also
known as ILT2, CD85j, or LILRB1) (16). LIR-1 is expressed on
most or all monocytes, dendritic and B cells, and subsets of T cells
and NK cells, where it functions as an inhibitory receptor by virtue
of inhibitory motifs in its cytoplasmic tail and association with
SHP-1, a tyrosine phosphatase that inhibits activating signals (15).
Unlike the related killer inhibitory receptors (KIRs) on NK cells,
which show allele-specific binding to class I MHC molecules (17),
LIR-1 and its relative LIR-2 bind a broad range of classical and
nonclassical class IMHCproteins (18, 19). Structural and biochem-
ical results suggest that LIR-1 uses a common binding interaction
to recognizeUL18 and class IMHCmolecules, but it binds toUL18
with a1,000-fold higher affinity (18). Crystal structures of LIR-1
(20), LIR-2 (21), and their complexes with classical (HLA-A2) (22)
and nonclassical (HLA-G) (23) class I MHC molecules revealed
that the LIR proteins bind to the relatively conserved 3 domain of
the heavy chain and to the invariant 2m light chain, rationalizing
the broad cross-reactivity of these receptors.
Structural studies involving UL18 have been hindered by its
heavy glycosylation. Here we report the 2.2-Å crystal structure of
a complex between LIR-1 and a glycosylation-deficient UL18
occupied with an actin-derived peptide. The structure reveals a
surprising mimicry of classical class I MHC peptide, suggests that
carbohydrates prevent interactions withmany potential UL18 bind-
ing partners, and explains how UL18 binds more tightly than host
MHC proteins to LIR-1, demonstrating how a viral protein can
effectively compete with host proteins for a receptor to subvert the
host immune response.
Results and Discussion
Production of Glycosylation-Deficient UL18 for Crystallization. UL18
contains 13 potential N-glycosylation sites, compared with one
in human class I MHC molecules (11). When expressed in
mammalian cells, the ectodomain of UL18 was heavily (55%
carbohydrate by weight) and heterogeneously glycosylated (18)
and therefore unsuitable for forming well ordered crystals. We
produced a more homogeneous form of UL18 by expressing
soluble UL18/2m heterodimers in insect cells, which attach
relatively small N-linked oligomannose structures (24), and
removing 3 of the 13 potential N-linked sites chosen as described
in the supporting information (SI) Materials and Methods. An
actin-derived peptide (ALPHAILRL) previously identified as
associating with UL18 (13) was added during purification. The
resulting mutant protein formed a peptide-binding heterodimer
with 2m, showed a reduction in apparent molecular mass of its
heavy chain consistent with removal of N-linked carbohydrate,
and bound LIR-1 with an affinity similar to that of wild-type
UL18 (data not shown).
Crystals were produced from a 1:1 complex between a mutant
UL18 and the UL18-binding and class-I-MHC-binding domains of
LIR-1, domains 1 and 2 (D1 and D2), respectively. Elimination of
one of the N-glycosylation sites (Asn-147) in UL18 was critical for
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crystallization because this region of UL18 was in a crystal contact.
A structure was refined to 2.6-Å resolution (Rcryst 22.2%, Rfree
25.1%; Table S1) by using data from crystals that had not been
supplemented with peptide. Although both proteins were well
ordered, the electron density for the actin peptide was poor,
suggesting that a mixture of peptide-filled and empty UL18 had
been crystallized. A subsequent UL18/LIR-1 structure with a fully
loaded UL18 peptide-binding groove was refined to 2.2 Å (Rcryst
24.1%,Rfree 25.9%;Table S1) by using data fromcrystals that had
been incubated with excess peptide. Although there were slight
differences in crystal packing, the structures were similar (rmsd of
0.4 Å calculated for all C atoms), suggesting that peptide binding
does not significantly alter the UL18 structure, which is consistent
with studies showing that empty, partially filled, and fully peptide-
loaded UL18 bind similarly to LIR-1 (18). Structural analyses were
done by using the 2.2-Å structure involving fully peptide-loaded
UL18.
Overview of the UL18/LIR-1 Complex Structure. The structures of
individual proteins in the LIR-1/UL18 complex resembled their
counterparts in structures of the LIR-1/HLA-A2 complex (22) and
of LIR-1 or LIR-2 proteins alone (20, 21) (Fig. 1). UL18 and host
class I MHC molecules are composed of a heavy chain with an
1-2 peptide-binding platform and a membrane-proximal 3
domain, a bound peptide, and a noncovalently associated 2m light
chain. Despite sharing only 25% sequence identity, the UL18
heavy chain was remarkably similar to its MHC counterparts in
overall structure and association with bound peptides and 2m.
In both types of protein, the peptide-binding 1-2 superdomain
(Figs. 1 A–C and 2) is positioned on top of the Ig-like 3 and 2m
domains.
LIR-1 D1-D2 consists of two nearly orthogonal Ig superfamily
domains (20). Both LIR-1 domains in the UL18/LIR-1 complex
were structurally similar to their counterparts in previous structures
(rmsd 1 Å for individual domain superpositions), but their
orientationwith respect to each other was different in the structures
of free LIR-1, UL18-bound LIR-1, and HLA-A2-bound LIR-1
(Fig. 1E). When the D1 domains of LIR-1 pairs were superim-
posed, the rmsd for the 87 C atoms in the D2 domain was 3.0 Å
(free LIR-1 versus UL18-bound LIR-1), 4.8 Å (free LIR-1 versus
HLA-A2-bound LIR-1), and 3.7 Å (UL18-bound LIR-1 versus
HLA-A2-bound LIR-1).
As observed in the LIR-1/HLA-A2 complex, the LIR-1/UL18-
binding interaction involved two distinct surfaces on each binding
partner, with the D1-D2-interdomain-hinge region contacting 2m
(site 1) and the tip of the LIR-1 D1 domain contacting the UL18
3 domain (site 2) (Fig. 1 A and B). Variable residues in the UL18
1 domain, identified by sequence analysis of 21 clinical and
laboratory isolates (Fig. 2 and Fig. S1), were predicted to contact
LIR-1 (25, 26); however, there are no UL18-1-domain residues
within 4 Å of LIR-1 D1-D2. Although LIR-1 D3-D4, which is not
present in the crystals, could contact this region of UL18, analytical
ultracentrifugation data suggested an extended structure for LIR-1
D1-D4 (18), whereas a substantial bend would be required to
achieve D3-D4 contacts with UL18 1. In addition, the affinities of
D1-D4 and D1-D2 for UL18 did not differ significantly (18), which
is consistent with no critical contacts between LIR-1 D3-D4
and UL18.
The C termini of the UL18 ectodomain and the LIR-1 D1-D2
fragment were oriented in opposite directions, which is most
consistent with a trans interaction on opposing membranes (Fig.
1A). A cis interaction on the same membrane between LIR-1 and
class I MHC molecules has been proposed (27) but is hard to
rationalize when analytical ultracentrifugation data suggest an
extended LIR-1 structure (18), because a cis interaction would
require LIR-1 D3, D4, and the C-terminal residues before the
transmembrane region to nearly reverse directions compared
with D1-D2.
Comparison of UL18 with Classical Class I MHC and MHC Homolog
Structures. In a comparison of UL18 with other class I MHC
homologs that share similar or higher percent sequence identities
with classical class I MHC proteins, including CD1, HFE, FcRn,
ZAG,MIC-A,M10.5, T-22, and the viral class I homologsm144 and
m157, UL18 was the most similar to host class I molecules by virtue
of being the only homolog to contain an open and peptide-occupied
groove (Fig. S2). Thus, unlike the structures of MHC homologs
with closed grooves, the -helices in the UL18 and HLA-A2
peptide-binding platforms were separated by a similar distance
(Fig. 1C). The actin-derived ALPHAILRL peptide assumed an
extended conformation in the UL18 groove, similar to the confor-
mations of nonamer peptides bound to HLA-A2 and other class I
MHC molecules (Fig. 1D and Fig. S3; see the SI Discussion for a
detailed comparison). Despite several insertions and deletions in
aligned sequences of the peptide-binding domains of UL18 and
class I MHC molecules (Fig. 2), superposition of the UL18 and
HLA-A2 1-2 domains (Fig. 1C) (rmsd 0.5 Å for 50 C atoms)
revealed that the changes were usually accommodated without
generating the protruding loops that had been suggested by com-
putational modeling of the UL18 structure (25, 26, 28).
Minor differences between the UL18 and HLA-A2 structures
Fig. 1. Structure of UL18/LIR-1 and comparisonwith HLA-A2/LIR-1. (A and B)
Ribbon diagrams of the UL18/LIR-1 (A) and HLA-A2/LIR-1 (B) complexes.
Disulfidebondsare thick yellowsticks, andordered carbohydratesonUL18are
thin yellow sticks. A predicted O-glycosylation site in the UL18 ectodomain is
indicated by an orange sphere, and the single N-glycosylation site on HLA-A2
is indicated as a yellow sphere. (C) C superposition of the peptide-binding
platforms of UL18 and HLA-A2. Insertions in UL18 are in blue on the UL18
structure, and deletions in UL18 are black on the HLA-A2 structure. (D) The
ALPHAILRL peptide model superimposed on a 2.2-Å 2Fo  Fc annealed omit
electron density map contoured at 1.0 . (E) Stereo superposition of C traces
of LIR-1 D1-D2 structures after superposition of the D1 domains.
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included the relative orientation between the3 domain and1–2
platform (Fig. S2), which differed slightly due in part to a four-
residue deletion in UL18 at a position corresponding to the short
helix in class IMHCmolecules that connects the2 and3 domains
(class I residues 175–178) (Fig. 2). Due to differences in this region
and in the loop connecting the 1 and 2 domains in the platform
(Fig. 1C), theUL18 heavy chainmademore contacts with2m than
did the HLA-A2 heavy chain, leading to a somewhat larger total
buried surface area in the UL18/2m interface (2,900 Å2) than in
the HLA-A2/2m interface (2,700 Å2). The UL18 heavy chain also
differed from the class I MHC molecules in that three, rather than
two, disulfide bonds were present. In addition to the conserved
disulfide bonds in the 2 and 3 domains found in class I MHC
molecules and homologs (UL18 residues Cys-102–Cys-174 and
Cys-209–Cys-265), the UL18 3 domain included a disulfide bond
linking strands D and E (Cys-238–Cys-253) (Fig. 1A). Both 3
domain disulfide bonds are critical for UL18 stability because
disruption of either of them abolished the association with2m and
the binding to LIR-1 (25, 28).
Comparison of LIR Binding to UL18 and Host Class I MHC Proteins. The
residues in the site 1 interaction were very similar in the LIR-1/
UL18 and LIR-1/HLA-A2 complexes (Fig. 3 and Table 1). In
contrast, residues in the site 2 interaction differed, as expected given
the sequence differences between the two 3 domains. The se-
quence differences, combined with slight conformational changes,
created a more favorable binding interface at the UL18 site 2
interface with LIR-1. For example, the UL18 site 2 interface
included salt bridges (UL18 Asp-202–LIR-1 Arg-36, UL18 Glu-
235–LIR-1 Lys-41), hydrogen bonds (UL18 Asn-201–LIR-1 Leu-
37, UL18 Asp-233 and Gln-237–LIR-1 Lys-41, UL18 Asn-199 and
Glu-206–LIR-1 Thr-43), van der Waals contacts, and water-
mediated hydrogenbonds (Table S2), whereasmost of theHLA-A2
site 2 interface consisted of van der Waals interactions. Residues
from three regions in UL18 3 contacted LIR-1 (Fig. 3A): the loop
between strand A and B (residues 199–206), the loop between
strand C and D (residues 231–237), and residues from strand E
(residues 254–256). Only residues from the first and third regions
were at the LIR-1/HLA-A2 interface. Asp-202 of UL18 (HLA-A2
residue Asp-196), which formed a salt bridge with Arg-36 of LIR-1
and van der Waals contacts with Tyr-76 in both structures, was the
only conserved residue in site 2. This residue is conserved through-
out LIR-1-binding classical and nonclassical class IMHCmolecules
but is substituted nonconservatively in the MHC homologs HFE,
FcRn, and ZAG, which do not bind LIR-1 (Fig. 3A) (18, 22).
The total solvent-accessible surface area buried at the LIR-1/
UL18 interface (2,200 Å2) was higher than the areas of typical
protein–protein recognition interfaces (1560–1700Å2) (29) and the
LIR-1/HLA-A2 interface (1700 Å2) (Fig. 4 A and B). In the
heavy-chain-specific binding surface (site 2), LIR-1 made more
contacts with UL18 3 than with HLA-A2 3 (Table 1 and Fig. 3),
and consequently the total buried surface area at this site increased
Fig. 2. Structure-based sequencealignmentofUL18andHLA-A2. Secondary structures are indicatedas arrows for-strands and springs for-helices. Conserved
residues are shown as white letters in red boxes, and conservative substitutions are indicated as red letters. UL18 residues that vary between clinical and
laboratory isolates of HCMV (identified by using 21 unique HCMV sequences available in the NCBI protein database, www.ncbi.nlm.nih.gov/) are indicatedwith
a purple dot above the UL18 sequence. Highly variable residues, defined as described previously (46), are indicated by purple dots below the HLA-A2 sequence.
The asparagines in potential N-glycosylation sites in both sequences are marked with green stars. Residues in each peptide binding groove are indicated as
upward-pointing black triangles. Residues that interact with LIR-1 are marked with downward-pointing blue triangles.
Fig. 3. Sequence comparisons of residues at LIR-
contacting positions. Red, blue, and yellow indicate non-
conservatively substituted, conservatively substituted,
and conserved positions, respectively. (A) Comparison of
the LIR-1-binding (LIR-2-binding for HLA-G) epitope on
the 3 domains of UL18, HLA-A2, and HLA-G. Residues
contactingLIR-1orLIR-2 (4.0Å)arecircled.Correspond-
ing residues on class I MHC homologs that do not bind
LIR-1 or LIR-2 are also listed. (B) Comparison of 3- and
2m-contacting residues on LIR-1 (LIR-2 forHLA-G) in the
LIR-1/UL18,LIR-1/HLA-A2,andLIR-2/HLA-Gcomplexes. In-
teracting ( 4.0 Å) residues are circled.
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from 500 Å2 in the LIR-1/HLA-A2 complex to 1200 Å2 for
LIR-1/UL18. In contrast, there was slightly less buried surface area
at site 1 in the LIR-1/UL18 complex (1,000 Å2) than in the
LIR-1/HLA-A2 complex (1,200 Å2). Thus the majority of the
contacts between LIR-1 and UL18 involved the UL18-specific
portion of the UL18/2m heterodimer, whereas the LIR-1 inter-
actionwithHLA-A2 involved amajority of contacts to the invariant
2m light chain.
The UL18-specific portion of the LIR-1/UL18 interface was also
more complementary than the LIR-1/HLA-A2 interface, as as-
sessed by the shape complementarity index (SC) (30), an index that
ranges from 0 (not complementary) to 1 (a perfect fit). The site 1
interaction, although rather large in the LIR-1/HLA-A2 complex,
was not particularly complementary comparedwith its LIR-1/UL18
counterpart (SC values of 0.76 and 0.61 for the LIR-1/UL18 and
LIR-1/HLA-A2 complexes, respectively). By comparison, SC values
are 0.64–0.68 for typical antibody/antigen interfaces (30). The SC
value was 0.59 for the site 2 interaction in the LIR-1/UL18 complex
and 0.57 in the LIR-1/HLA-A2 complex. The LIR-2 interaction
with HLA-G (23) also involved a large (2,200 Å2) (Fig. 4C) but
not particularly complementary interface (SC values of 0.61 and
0.51 for sites 1 and 2, respectively). The combination of increased
contacts, a large buried surface area, and optimal surface comple-
mentarity explains why LIR-1 binds 1,000-fold more tightly to
UL18 (Kd  4.0 nM) than it binds to HLA-A2 and other class I
molecules (18) and 500-fold more tightly than LIR-2 binds to
HLA-G (19).
Comparisons of the UL18/LIR-1, LIR-2, and HLA-G/LIR-2
structures (21, 23) explainwhyUL18binds3,000-foldmore tightly
to LIR-1 than to LIR-2 (18). An overall similarity between the D2
domains of LIR-1 and LIR-2 suggests that interactions with 2m at
site 1 would be preserved in the UL18/LIR-2 interaction. However,
a nonconservative substitution in LIR-2 (LIR-1 Ile-100 for LIR-2
Pro-99) might weaken the binding to LIR-2 (Fig. 3B). In addition,
one of the loops in LIR-1 D1 that makes contacts with UL18 3 in
site 1 (LIR-1 residues 77–86; LIR-2 residues 77–85) showed an
altered conformation in the LIR-2 structures (21, 23), such that a
loop with this conformation would not contact UL18 in a LIR-2/
UL18 complex. A LIR-2 mutant in which LIR-1 residues were
introduced into this loop (Q76Y/R80D/W83RLIR-2) boundUL18
10- to 30-foldmore tightly than did wild-type LIR-2 (20), suggesting
the potential for flexibility and demonstrating that the wild-type
LIR-2 sequence is not optimal for UL18 binding. Thus decreased
interactions in both the site 1 and site 2 interfaces in a UL18/LIR-2
complex are predicted to be responsible for the lower affinity of
LIR-2 versus LIR-1 for UL18.
UL18 Carbohydrates Prevent Interactions with Potential Binding Part-
ners. One of the major differences between UL18 and host class I
MHCmolecules is the large amount of carbohydrate resulting from
UL18’s 13 potential N-glycosylation sites as compared to the single
N-glycan attached to human class I MHC molecules. Ordered
carbohydrate was observed at 5 of the 10 potential N-linked sites in
the UL18 mutant that was crystallized but not at the single
predicted O-glycosylation site (Fig. 1A). Although much of the
UL18 carbohydrate was disordered in the LIR-1/UL18 crystal
structure, the molecular mass of purified UL18 protein suggests
that most, if not all, of its N-linked sites are glycosylated (18). In
addition, the 13 potential N-linked sites are conserved in 21 unique
UL18 sequences from sequencedHCMV genomes (Fig. S1). Using
the coordinates of a typical mammalian N-linked glycan, which can
extend up to 30 Å from the asparagine in an Asn-Xaa-Ser/Thr
N-glycosylation site (31), we modeled the structure of fully glyco-
sylated UL18 bound to LIR-1 (Fig. 5A). Most of the available
surface area on the UL18 heavy chain was predicted to be covered
with N-linked carbohydrate, particularly the 1–2 peptide binding
platform of UL18, which includes 10 of 13 potential glycosylation
sites (Fig. 5B). Two notable regions lacked carbohydrate: the
binding site for LIR-1 and the interaction interface with 2m,
suggesting that UL18 evolved to hide other potential binding
surfaces, thereby preventing interactions with binding partners of
host class I MHC molecules.
To assess the effects of UL18’s glycosylation on potential binding
interactions, we evaluated the binding sites for class IMHC binding
partners by using the fully glycosylated UL18 model. T cell recep-
tors (TCRs) bind across the 1–2 domain helices, contacting the
bound peptide (32). Although the UL18 1-2 helices and associ-
ated peptide are structurally very similar to a class I MHC/peptide
complex, it is unlikely that a TCR could contact the UL18-bound
peptide because four predicted N-linked glycans (attached to
Asn-75, Asn-147, Asn-157, andAsn-173) were located on theUL18
-helices surrounding and effectively shielding the bound peptide
(Fig. 5A). The footprint of NK cell KIRs involves a similar region
on class I MHC molecules (33), thus carbohydrates also likely
prevent KIR binding to UL18 (Fig. 5A). In addition, none of the
residues critical for class I binding to KIRs (33) are conserved in
UL18. Carbohydrates would also block binding of US2, one of
several HCMV-encoded proteins that bind to newly synthesized
class I MHC molecules in the endoplasmic reticulum, resulting in
down-regulation of surface expression (34). US2 binds at the
junction between the class I 1–2 platform and the 3 domain
(35); however, two class I MHC residues that interact with US2
(Asp-106 and Pro-267) are substituted by asparagines involved in
N-glycosylation sites inUL18 (Asn-107 andAsn-271) (Fig. 5C), and
UL18 has no equivalent of class I residue Arg-181, which plays an
critical role in binding toUS2 (36). Thus in anHCMV-infected cell,
UL18 should escape fromUS2-mediated down-regulation, whereas
host class I MHC molecules will not. A similar mechanism may
account for why UL18 is not susceptible to down-regulation by
either US3 or US11 (34).
Table 1. Comparison of amino acid contacts at the LIR-1/UL18
and LIR-1/HLA-A2 interfaces
LIR-1 UL18 HLA-A2
D1 UL18 HLA-A2
Arg-36 Asp-202* Asp-196*
Leu-37 Asn-201† None
Tyr-38 Asn-201, Arg-204, Asp-233 Val-194, Ser-195
Arg-39 None Val-194
Glu-40 Asp-233 None
Lys-41 Asp-233†, Glu-235*, Gln-237†,
Tyr-254, Ala-256
Val-194, Glu-198, Val-248
Lys-42 Tyr-254 None
Thr-43 Asn-199†, Glu-206† Ala-193
Thr-48 Gln-200, Asn-201 None
Tyr-76 Asp-202, Asn-203 Asp-196
Arg-84 Asp-202, Asn-203 None
D1 2m in LIR-1/UL18 2m in LIR-1/HLA-A2
Gln-18 Gln-89† Gln-89†
Lys-42 None Asp-96*
Trp-67 None Lys-91, Ile-92†, Val-93
Glu-68 None Lys-94
Gly-97 Ser-88 Ser-88
Ala-98 Leu-87, Ser-88† Leu-87, Ser-88
D2 2m in LIR-1/UL18 2m in LIR-1/HLA-A2
Tyr-99 Thr-4, Thr-86, Lys-91 Thr-4, Thr-86, Lys-91†
Ile-100 Gln-2, Val-85, Thr-86† Val-85, Thr-86†
Ser-124 Ile-1 None
Gln-125 Ile-1, Gln-2† Ile-1, Gln-2†
Val-126 Ile-1, Gln-2, Thr-4, Thr-86 Gln-2, Arg-3, Thr-4, Thr-86
Ala-127 Ile-1, Gln-2†, Arg-3 Gln-2†, Arg-3
Ser-155 Ile-1 None
Glu-184 Lys-91† Lys-91
Leu-187 Ser-88 Ser-88
*Salt bridge.
†Hydrogen bond.
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A combination of carbohydrate shielding as well as sequence and
conformational changes accounts for UL18’s inability to interact
with CD8, a T cell coreceptor that recognizes the3 domain of host
class I MHC molecules (37). Two predicted N-glycosylation sites
(Asn-103 andAsn-220)were near theUL18 counterpart of theCD8
binding surface (Fig. 5D). In addition, most of the residues involved
in the class I MHC interaction with CD8 were nonconservatively
substituted in UL18 (Fig. 5D), and the 3 domain loop critical for
CD8 binding to class I MHC molecules (37) was differently
positioned in UL18 (Fig. 5D).
Significance of Peptide Binding by UL18. Bound peptide is distant
from the LIR-1 binding site (Fig. 1A) and not required for UL18
to bind to LIR-1 (18). Thus although the UL18/LIR-1 structure
provided a clear picture of how UL18 preferentially binds short
peptides with P2 (Leu orMet), P3 (Pro), and P9 (small hydrophobic
residue) anchor positions (Fig. S3 and Table S3), it did not address
the function of peptide binding. Of possible relevance is whether
UL18 proteins from different HCMV strains show the same or
different peptide-binding preferences. Although allelic polymor-
phism in classical class I MHC molecules mapped mainly to the
MHC peptide-binding groove, thereby creating different allele-
specific peptide-binding preferences (38), variability in UL18 se-
quences from different laboratory and clinical strains of HCMV
systematically mapped to regions other than the UL18 peptide-
binding groove (Fig. 2). Because UL18 variability does not create
an opportunity for different strain-specific peptide-binding prefer-
ences, most or all UL18 proteins are likely to bind a similar class of
peptides.
To address whether UL18 might sequester HCMV peptide
epitopes from host class IMHCmolecules, we investigated whether
peptides conforming to the UL18-specific peptide-binding motif
were present in the HCMV genome. We found 30 nonameric
sequences in the genome of HCMV AD169 that conform to the
UL18 binding motif (Fig. S4), thus UL18 could associate with viral
as well as host peptides. However, a peptide-sequestering function
seems unlikely given that only low levels of UL18 are expressed on
virally infected cells (39) and UL18’s strict peptide-binding prefer-
ences would allow sequestering from only a few class IMHCalleles,
such as HLA-A2, whose peptide-binding motif is similar to that of
UL18. Alternatively, peptide binding could be required to stabilize
theUL18 fold (18) or for binding to an as yet undiscovered immune
receptor, as previously hypothesized (40). However, direct contacts
to the bound peptide are unlikely due to carbohydrate shielding
(Fig. 5B).
Further studies will be required to understand why UL18, alone
among viral class I MHC homologs, associates with endogenous
peptides and what effects peptide binding has on the HCMV
lifecycle and the host anti-viral immune response. The high-
resolution UL18/LIR-1 structure allows the rational design of
mutants that cannot bind peptides or bind a different class of
peptides, which could be tested in viral and/or immunological
assays.
Fig. 4. Surface representations of LIR proteins and their binding partners.
Contact surfaces (4.0 Å) are highlighted in yellow. (A) UL18, UL18/LIR-1, and
LIR-1. An asterisk marks the position of a LIR-1 loop (residues 148–154) that is
disordered in the UL18/LIR-1 complex structure. (B) HLA-A2, HLA-A2/LIR-1, and
LIR-1 (PDB ID code 1P7Q). (C) HLA-G, HLA-G/LIR-2, and LIR-2 (PDB ID code 2DYP).
Fig. 5. Interaction sites for potential binding partners highlighted on a fully
glycosylated UL18 model. (A) Space-filling representation of the UL18/LIR-1
complex (UL18 in magenta, 2m in slate, peptide in light green, LIR-1 in cyan)
with a complex carbohydrate model (yellow) attached to each of the 13
potential N-glycosylation sites. The single predicted O-glycosylation site (res-
idue 281) within the UL18 ectodomain is indicated by an orange sphere. Two
to threeadditionalO-glycosylation sites arepredicted in the regionC-terminal
to the UL18 ectodomain fragment that was crystallized, but these sites would
be distant from the binding sites for all potential UL18 binding partners. The
UL18 counterparts of the approximate binding sites on a class I MHCmolecule
for a TCR or KIR are indicated by arrows. (B) Top view of the fully glycosylated
UL18 peptide binding platform. (C) Potential US2 binding site (dark green) on
fully glycosylated UL18. (D) Potential CD8 binding site (dark green) on fully
glycosylated UL18. An enlarged view of the CD8-binding loop in the class I
MHC 3 domain (gray) is shown with the counterpart UL18 loop (magenta).
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Materials and Methods
For further experimental details, see the SI Materials and Methods.
Mutant UL18 (N36Q/N147Q/N220Q/C259S)/ALPHAILRL peptide complexes
and LIR-1 D1-D2 were produced as described in the SI Materials and Methods.
Two native data sets were collected at 100 K from LIR-1/UL18 complex crystals at
the Stanford Synchrotron Radiation Laboratory. The first data set was collected
from untreated crystals, and the second was collected from crystals grown from
protein solutions supplemented with 2.5 mM ALPHAILRL peptide. Data were
processed by using the HKL2000 program (41). The structure was determined by
molecular replacement (42) using a LIR-1/HLA-A2 (22) searchmodel and the first
data set (Table S1). After rigid-body refinement (42), rebuilding was done by
using the programO and 2Fo Fc annealed omit maps, alternating with refine-
ment using the CNS program (43). Noncrystallographic symmetry restraints (300
kcal/molÅ2) and individual B factor refinement were used during refinement. A
finalmodelat2.6-Å resolution (Rcrys22.2%,Rfree25.1%)consistedof residues
1–280 of the UL18 heavy chain; 2m residues 1–99; and LIR-1 residues 4–77,
83–136, 143–147, 155–166, and 170–198. Density for the ALPHAILRL peptide
was poor.
The structure was solved again by using data from the second data set (Table
S1) (collected from crystals treated with excess peptide) by molecular replace-
mentusing the refined2.6-ÅUL18/LIR-1 structure. Clear densitywas visible for all
nineresiduesofthepeptide,UL18,2m,andmostofLIR-1.Themodelwasrefined
to 2.2-Å resolution (Rcryst  24.1%, Rfree  25.9%). The final model consisted of
residues 1–281 of UL18; peptide residues 1–9; 2m residues 1–99; LIR-1 residues
4–136, 143–147, 155–198; 362 water molecules, and 214 atoms of carbohydrate
(ordered carbohydrate attached to UL18 residues Asn-54, Asn-103, Asn-157,
Asn-173, andAsn-271). The side chainsofUL18 residues140and229;2m58;and
LIR-1 31, 156, and 168 were modeled as alanines. The following cysteine pairs
were disulfide bonded: LIR-1 26–75, 122–174, 134–144, UL18 102–174, 209–265,
238–253, and 2m 25–80.
For analysis of contacts and buried surface areas, D1 was defined as residues
1–98 and D2 was defined as residues 99–198. The CCP4 program Areaimol (44)
was used to calculate buried surface areas using a 1.4-Å probe and to identify
interacting residues using the following criteria: a distance of 3.5 Å and a
hydrogen bond angle of90° for hydrogen bonds and a maximum distance of
4.0 Å for a van der Waals interaction. Shape complementarity indices were
calculated as described previously (30) by using the Sc program in CCP4 (44).
Figures were prepared with PyMOL (45).
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